Search hospitals > Massachusetts > Springfield

Mercy Medical Center

Claim this profile
Springfield, Massachusetts 01104
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Tumors
159 reported clinical trials
5 medical researchers
Photo of Mercy Medical Center in SpringfieldPhoto of Mercy Medical Center in SpringfieldPhoto of Mercy Medical Center in Springfield

Summary

Mercy Medical Center is a medical facility located in Springfield, Massachusetts. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Tumors and other specialties. Mercy Medical Center is involved with conducting 159 clinical trials across 332 conditions. There are 5 research doctors associated with this hospital, such as Tareq Al Baghdadi, Christopher M. Reynolds, MD, Philip J. Stella, and Elie G. Dib.

Area of expertise

1Cancer
Global Leader
Mercy Medical Center has run 37 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Breast Cancer
Global Leader
Mercy Medical Center has run 28 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
HER2 negative
ER positive

Top PIs

Clinical Trials running at Mercy Medical Center

Non-Small Cell Lung Cancer
Bladder Cancer
Bladder Carcinoma
Lung Cancer
Cancer
Renal Cell Carcinoma
Gastric Cancer
Esophageal Adenocarcinoma
Squamous Cell Carcinoma
Small Intestinal Adenocarcinoma
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Image of trial facility.

Osimertinib

for Non-Small Cell Lung Cancer

This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back (recurrent). Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Recruiting1 award Phase 242 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Mercy Medical Center?
Mercy Medical Center is a medical facility located in Springfield, Massachusetts. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Tumors and other specialties. Mercy Medical Center is involved with conducting 159 clinical trials across 332 conditions. There are 5 research doctors associated with this hospital, such as Tareq Al Baghdadi, Christopher M. Reynolds, MD, Philip J. Stella, and Elie G. Dib.